525 related articles for article (PubMed ID: 28263914)
21. In vivo analysis of supersaturation/precipitation/absorption behavior after oral administration of pioglitazone hydrochloride salt; determinant site of oral absorption.
Tanaka Y; Sugihara M; Kawakami A; Imai S; Itou T; Murase H; Saiki K; Kasaoka S; Yoshikawa H
Eur J Pharm Sci; 2017 Aug; 106():431-438. PubMed ID: 28603033
[TBL] [Abstract][Full Text] [Related]
22. In vivo evaluation of supersaturation/precipitation/re-dissolution behavior of cinnarizine, a lipophilic weak base, in the gastrointestinal tract: the key process of oral absorption.
Tanaka Y; Kawakami A; Nanimatsu A; Horio M; Matsuoka J; Wada T; Kasaoka S; Yoshikawa H
Eur J Pharm Sci; 2017 Jan; 96():464-471. PubMed ID: 27773836
[TBL] [Abstract][Full Text] [Related]
23. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility.
Gu CH; Rao D; Gandhi RB; Hilden J; Raghavan K
J Pharm Sci; 2005 Jan; 94(1):199-208. PubMed ID: 15761943
[TBL] [Abstract][Full Text] [Related]
24. Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.
Hens B; Bermejo M; Tsume Y; Gonzalez-Alvarez I; Ruan H; Matsui K; Amidon GE; Cavanagh KL; Kuminek G; Benninghoff G; Fan J; Rodríguez-Hornedo N; Amidon GL
Eur J Pharm Sci; 2018 Mar; 115():258-269. PubMed ID: 29378253
[TBL] [Abstract][Full Text] [Related]
25. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.
Zhou R; Moench P; Heran C; Lu X; Mathias N; Faria TN; Wall DA; Hussain MA; Smith RL; Sun D
Pharm Res; 2005 Feb; 22(2):188-92. PubMed ID: 15783065
[TBL] [Abstract][Full Text] [Related]
26. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution.
Takeuchi S; Tsume Y; Amidon GE; Amidon GL
J Pharm Sci; 2014 Nov; 103(11):3416-3422. PubMed ID: 25251982
[TBL] [Abstract][Full Text] [Related]
28. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
[TBL] [Abstract][Full Text] [Related]
29. An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products.
Gonzalez-Alvarez I; Bermejo M; Tsume Y; Ruiz-Picazo A; Gonzalez-Alvarez M; Hens B; Garcia-Arieta A; Amidon GE; Amidon GL
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917118
[TBL] [Abstract][Full Text] [Related]
30. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
Macheras P; Iliadis A; Melagraki G
Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
[TBL] [Abstract][Full Text] [Related]
31. Application of an In Vitro Dissolution/Permeation System to Early Screening of Oral Formulations of Poorly Soluble, Weakly Basic Drugs Containing an Acidic pH-Modifier.
Mizoguchi M; Kataoka M; Yokoyama K; Aihara R; Wada K; Yamashita S
J Pharm Sci; 2018 Sep; 107(9):2404-2410. PubMed ID: 29802932
[TBL] [Abstract][Full Text] [Related]
32. Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model.
Jede C; Wagner C; Kubas H; Weigandt M; Weber C; Lecomte M; Badolo L; Koziolek M; Weitschies W
Mol Pharm; 2019 Sep; 16(9):3938-3947. PubMed ID: 31335153
[TBL] [Abstract][Full Text] [Related]
33. Evaluating supersaturation in vitro and predicting its performance in vivo with Biphasic gastrointestinal Simulator: A case study of a BCS IIB drug.
Gan Y; Zhang X; Xu D; Zhang H; Baak JP; Luo L; Xia Y; Wang J; Ke X; Sun P
Int J Pharm; 2020 Mar; 578():119043. PubMed ID: 31962190
[TBL] [Abstract][Full Text] [Related]
34. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
35. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.
Kambayashi A; Dressman JB
J Pharm Sci; 2019 Jan; 108(1):584-591. PubMed ID: 30423339
[TBL] [Abstract][Full Text] [Related]
36. An Artificial Gut/Absorption Simulator: Simultaneous Evaluation of Desupersaturation and Absorption from Ketoconazole Supersaturated Solutions.
Jain KMH; Hou HH; Siegel RA
J Pharm Sci; 2023 Aug; 112(8):2212-2222. PubMed ID: 36162494
[TBL] [Abstract][Full Text] [Related]
37. Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs.
Li M; Zhang X; Wu D; Anand O; Chen H; Raines K; Yu L
AAPS J; 2021 Oct; 23(6):113. PubMed ID: 34704158
[TBL] [Abstract][Full Text] [Related]
38. Impact of amorphization and GI physiology on supersaturation and precipitation of poorly soluble weakly basic drugs using a small-scale in vitro transfer model.
Auch C; Jede C; Harms M; Wagner C; Mäder K
Int J Pharm; 2020 Jan; 574():118917. PubMed ID: 31811926
[TBL] [Abstract][Full Text] [Related]
39. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
40. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
